Cure8 research brief
A simpler capillary self-collection device plus a Bayesian prediction tool could expand access to therapeutic drug monitoring and precision-guided dosing for infliximab, reducing the need for venous draws and potentially enabling more timely dose adjustments.
Patients on infliximab or other anti-TNF biologics, clinicians involved in IBD therapeutic drug monitoring or dosing, and researchers developing remote sampling or PK-guided dosing tools.
The researchers compared midcycle capillary self-collected samples with standard venous samples and used a nonlinear mixed-effects model with Bayesian priors to predict trough infliximab concentrations.
They report strong correlation between capillary and venous measurements and between PredictrPK-predicted and measured trough levels, in a cohort of 57 patients and 97 paired samples.
The study was performed at a single IBD center during maintenance infliximab therapy; the abstract reports high agreement but does not provide detailed subgroup or clinical outcome data here. Larger, multicenter validation and assessment of how PGD-guided dosing affects clinical outcomes would be important next steps.
Practical note: This brief summarizes the article abstract from the journal Inflammatory Bowel Diseases; it does not replace reading the full paper or clinical guidance.
This classification and brief are based on the article abstract (Inflammatory Bowel Diseases). The study is single-center with 57 patients and 97 paired samples; the abstract reports correlation metrics but not long-term clinical outcomes or broad external validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.
